Geron Highlights Imetelstat Data at Key Hematology Congresses
Event summary
- Geron presented data on imetelstat at the 88th Annual Meeting of the Japanese Society of Hematology and the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology.
- Real-world U.S. claims data showed 67% of patients remained on imetelstat therapy at 6 months despite substantial comorbidity burden.
- Korean patients exhibited durable efficacy and manageable safety with imetelstat, with early cytopenias associated with better clinical outcomes.
- Integrated molecular findings from the IMerge trial suggested imetelstat may alter the underlying biology of lower-risk MDS.
The big picture
Geron's presentations at major hematology congresses underscore the growing global interest in imetelstat, particularly in lower-risk myelodysplastic syndromes (LR-MDS). The focus on real-world evidence and clinical outcomes aligns with broader industry trends toward personalized medicine and data-driven treatment decisions. Geron's ability to leverage these insights could enhance its competitive edge in the hematology space, particularly as it explores opportunities to expand imetelstat's use in other hematologic malignancies.
What we're watching
- Global Expansion
- Whether Geron can successfully expand imetelstat's reach beyond the U.S. and into European and Asian markets.
- Clinical Validation
- How the emerging real-world evidence and molecular findings will impact the clinical validation of imetelstat.
- Competitive Positioning
- The pace at which Geron can solidify imetelstat's position as a first-in-class treatment for lower-risk MDS.